Despite the discordance of HER2 negative primary tumors and HER2 positive CTC reported in breast cancer, in lung cancer, a recent study analyzed the PD-L1 expression on CTCs, cytology imprints and tissue samples of NSCLC patients. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.